Recorded September 29, 2015

Sponsored by
 

Webinar Description:

The clinical oncology laboratory is faced with challenges in monitoring the quality of their genetic analyses. Next-generation sequencing, an important tool for tumor profiling, adds another level of complexity to ensure highly reproducible results.

Learning Objectives:

• Understand sources of variation for NGS-based clinical oncology assays
• Learn quality control practices currently used at Dartmouth Hitchcock Medical Center
• Learn how SeraCare Life Sciences can assist both clinical assay developers and clinical laboratories

Speakers:

Dr. Russell Garlick

Chief Scientific Officer

SeraCare Life Science

Dr. Garlick has worked on the development, regulatory approval and launch of a variety of technologies and assays, including an HIV AIDS patient management program, molecular genomics technologies and HIV drug discovery systems. Prior to joining SeraCare, he was co-founder of Life Sciences Group and also served as CEO and CTO of Protein Forest, Inc. Dr. Garlick also held executive R&D positions at PerkinElmer Life Sciences and DuPont NEN Life Sciences. Dr. Garlick has both a Ph.D. and M.S. in Biomedical Sciences, Medicinal Chemistry from the Barnett Institute at Northeastern University as well as a B.S. in Biology from University of Massachusetts at Lowell.

Dr. Francine Blumental de Abreu

Genomic Analyst

Translational Research Laboratory Dartmouth Hitchcock Medical Center

Dr. de Abreu is a Genomic Analyst in the Translational Research Laboratory, Department of Pathology at the Dartmouth Hitchcock Medical Center, under the direction of Dr. Greg Tsongalis. She received her Ph.D. in Biomedical Sciences at AC Carmago Hospital (Sao Paulo, Brazil) and her B.S. in Biomedicine from Sao Paulo State University (Sao Paulo, Brazil).

Moderator Information:

Dale Yuzuki, M.A., M.Ed.

Director of Market Development

Oncology at SeraCare Life Science